GLS — Glenmark Life Sciences Share Price
Last trade - 00:00- IN₹98.34bn
- IN₹94.10bn
- IN₹21.61bn
- 94
- 43
- 82
- 89
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.11 | ||
| Price to Tang. Book | 4.14 | ||
| Price to Free Cashflow | 30.5 | ||
| Price to Sales | 4.15 | ||
| EV to EBITDA | 12.53 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 28.55% | ||
| Return on Equity | 22.91% | ||
| Operating Margin | 29.58% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 8,864.21 | 15,373.13 | 18,851.65 | 21,232.14 | 21,612.2 | n/a | n/a | 24.96% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +60.11 | +12.1 | +24.17 | +7.56 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Glenmark Life Sciences Limited is an India-based company that is primarily engaged in the business of development, manufacture and marketing of active pharmaceutical ingredients (API). The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. The Company’s products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Ticagrelor, Telmisartan and Umifenovir. The Company’s research and development facilities are located at Mahape, Ankleshwar and Dahej in India and manufacturing facilities are located at Ankleshwar, Dahej, Mohol and Kurkumbh.
Directors
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 23rd, 2011
- Public Since
- August 6th, 2021
- No. of Shareholders
- 222,866
- No. of Employees
- 1,824
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 122,525,000
- Address
- Glenmark House, MUMBAI, 400099
- Web
- https://www.glenmarklifesciences.com/
- Phone
- +91 2268297979
- Contact
- Rudalf Corriea
- Auditors
- Walker Chandiok & Co LLP
Upcoming Events for GLS
Similar to GLS
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 19:09 UTC, shares in Glenmark Life Sciences are trading at IN₹802.65. This share price information is delayed by 15 minutes.
Shares in Glenmark Life Sciences last closed at IN₹802.65 and the price had moved by +79.64% over the past 365 days. In terms of relative price strength the Glenmark Life Sciences share price has outperformed the S&P BSE 100 Index by +39.33% over the past year.
There is no consensus recommendation for this security.
The Glenmark Life Sciences dividend yield is 5.42% based on the trailing twelve month period.
Last year, Glenmark Life Sciences paid a total dividend of IN₹43.50, and it currently has a trailing dividend yield of 5.42%. We do not have any data on when Glenmark Life Sciences is to next pay dividends.
We do not have data on when Glenmark Life Sciences is to next pay dividends. The historic dividend yield on Glenmark Life Sciences shares is currently 5.42%.
To buy shares in Glenmark Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹802.65, shares in Glenmark Life Sciences had a market capitalisation of IN₹98.34bn.
Here are the trading details for Glenmark Life Sciences:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: GLS
Based on an overall assessment of its quality, value and momentum Glenmark Life Sciences is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Glenmark Life Sciences. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +9.97%.
As of the last closing price of IN₹802.65, shares in Glenmark Life Sciences were trading +15.87% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Glenmark Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹802.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Glenmark Life Sciences' directors